Arterys Cardio DL vs Cleerly ISCHEMIA

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Arterys Cardio DL
by Arterys (now part of Tempus)
VS
Cleerly ISCHEMIA
by Cleerly

AI Verdict

Arterys Cardio DL and Cleerly ISCHEMIA are adjacent healthcare-AI tools, both leveraging AI for cardiac imaging analysis. Arterys Cardio DL specializes in automated ventricle segmentations and advanced flow analysis from cardiac MRI, aiming to streamline MRI interpretation. In contrast, Cleerly ISCHEMIA focuses on analyzing CCTA scans to non-invasively assess coronary artery ischemia and characterize plaque, aiding in the diagnosis and treatment planning for coronary artery disease. Their primary distinction lies in the imaging modality they process and the specific cardiac conditions they are designed to diagnose.

Choose Arterys Cardio DL if…

Choose Arterys Cardio DL if your primary need is rapid, automated, and editable ventricle segmentation and comprehensive analysis of cardiac MRI studies. This tool is ideal for clinicians seeking to drastically reduce interpretation time for cardiac MRIs, perform 4D Flow post-processing for blood flow visualization, and conduct quantitative delayed enhancement analysis.

View Arterys Cardio DL →

Choose Cleerly ISCHEMIA if…

Choose Cleerly ISCHEMIA if you require a non-invasive, AI-powered assessment of coronary artery disease using CCTA scans to determine the likelihood of vessel-level ischemia. This tool is best suited for physicians needing detailed coronary plaque characterization, stenosis severity assessment, and non-invasive fractional flow reserve (FFR) estimation to guide personalized treatment planning.

View Cleerly ISCHEMIA →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Arterys Cardio DL Cleerly ISCHEMIA
Pricing Unknown Contact for details
Deployment Cloud-based (SaaS), integrates with existing PACS or EHR, web-based zero-footprint viewer (Mac, PC, tablet, phone). [4, 7, 9, 13, 27] Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance)
FDA Status 1 AI-estimated 1 AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Arterys Cardio DL

Arterys Cardio DL emphasizes rapid analysis and editable automated contours, providing users with direct control and efficiency in their workflow. While Cleerly offers interactive reports and integration, the ability to edit AI-generated segmentations directly enhances user confidence and adaptability.

Clinical Value

Cleerly ISCHEMIA

Cleerly ISCHEMIA provides non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization, directly addressing a critical need in diagnosing and managing coronary artery disease. This offers a more direct and potentially impactful contribution to personalized diagnosis and treatment planning compared to general cardiac MRI analysis.

Pricing & Value

Tie

Both tools require direct contact for pricing information, making it impossible to compare their cost-effectiveness or value proposition without further details. Neither provides transparent pricing structures or comparative value metrics.

Enterprise Readiness

Cleerly ISCHEMIA

Cleerly ISCHEMIA explicitly details integration with PowerScribe via API and secure data transfer through Cleerly Proxy (VPN or virtual appliance), demonstrating robust enterprise integration capabilities. While Arterys Cardio DL offers vendor-agnostic compatibility, Cleerly's specific integration points indicate a more defined readiness for complex healthcare IT environments.

Innovation

Cleerly ISCHEMIA

Cleerly ISCHEMIA's non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization using AI on CCTA scans represent a significant innovation in cardiac diagnostics. This directly addresses a complex clinical challenge by providing novel, actionable insights without invasive procedures, pushing the boundaries of non-invasive CAD assessment.

Support & Docs

Tie

Neither the provided structured facts nor general web searches offer specific details regarding the depth, availability, or quality of support and documentation for either tool. Therefore, it is not possible to distinguish between them on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Arterys Cardio DL Cleerly ISCHEMIA
Name Arterys Cardio DL Cleerly ISCHEMIA
Company ARTERYS Cleerly
Description FDA-cleared, cloud-based AI software that provides automated, editable ventricle segmentations for cardiac MRI analysis, drastically reducing interpretation time and enhancing diagnostic accuracy. FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease.
Primary Imaging Modality Cardiac MRI CCTA scans
Key Feature 1 Automated ventricle segmentations for cardiac MRI AI-enabled CCTA analysis
Key Feature 2 Deep learning algorithms for image analysis Non-invasive fractional flow reserve (FFR) estimation

Videos

Demos, reviews, and walkthroughs featuring Arterys Cardio DL and Cleerly ISCHEMIA.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Arterys Cardio DL is designed for cardiac MRI analysis, providing automated ventricle segmentations. Cleerly ISCHEMIA, on the other hand, analyzes CCTA (Coronary CT Angiography) scans to assess coronary artery disease.
Arterys Cardio DL aims to drastically reduce interpretation time and enhance diagnostic accuracy for cardiac MRI analysis by automating ventricle segmentations. Cleerly ISCHEMIA focuses on non-invasively determining the likelihood of coronary artery ischemia at a vessel level from CCTA scans, aiding in personalized diagnosis and treatment planning for heart disease.
Arterys Cardio DL offers automated and editable ventricle segmentations, 4D Flow post-processing for blood flow visualization and quantification, and quantitative Delayed Enhancement analysis. Cleerly ISCHEMIA provides AI-enabled CCTA analysis, non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, coronary plaque characterization (volume, type, location), and stenosis severity assessment.
Arterys Cardio DL is vendor-agnostic and provides rapid analysis, aiming to streamline cardiac MRI interpretation. Cleerly ISCHEMIA offers comprehensive interactive web-based reports and integrates with PowerScribe via API, providing actionable information for personalized treatment planning.
Arterys Cardio DL is noted for drastically reducing cardiac MRI interpretation time, with rapid analysis completed in seconds compared to 30-60 minutes manually. Cleerly ISCHEMIA aids in personalized diagnosis and treatment planning, which can potentially reduce the need for additional testing.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Arterys Cardio DL or Cleerly ISCHEMIA

Backers

Who funded each tool's parent company.

Cleerly ISCHEMIA

AI Tool Finder
AI-powered search. Results may not be comprehensive.